Lack of activity of docetaxel in soft tissue sarcomas: Results of a phase II study of the Italian Group on Rare Tumors

Sarcoma

Volumn 3, Issue 3-4, 1999, Pages 177-181

  Santoro, Armando ^a   Romanini, Antonella ^b   Rosso, Alberto ^c   Frustaci, Sergio ^d   Comandone, Alessandro ^e   Apice, Gaetano ^f   De Toma, Domenico ^g   Dogliotti, Luigi ^h   Lionetto, Rita ⁱ   Dani, Carla ⁱ   Bruzzi, Paolo ⁱ   Piolini, Marco ^j   Bergnolo, Paola ^e   Verusio, Claudio ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Faculty of Medicine   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e GRADENIGO HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g IRCCS POLICLINICO SAN DONATO   (Italy)

^h SAN LUIGI GONZAGA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j c/o Istituto Clinico Humanitas ^*

more..

Author keywords

Docetaxel; Soft tissue sarcoma

Indexed keywords

DOCETAXEL;

ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; FEMALE; FEVER; FLUID RETENTION; HUMAN; HYPERSENSITIVITY; INFECTION; ITALY; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN TOXICITY; SOFT TISSUE SARCOMA; TREATMENT FAILURE; VOMITING;

EID: 0033509218     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149977613     Document Type: Article

References (19)

1. Santoro A, Soto Parra H. Sarcoma. In: Textbook of Medical Oncology 1999; in press.
2. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987;23:1477-83.
3. Bramwell VH, Mouridsen H, Santoro A, et al. Cyclophosphamide versus ifosfamide: final results of a randomized phase II trial in adult soft tissue sarcoma. Eur J Cancer Clin Oncol 1987;23:311-21.
4. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2:307-9.
5. Santoro A, Soto Parra H. Soft tissue and bone sarcomas. Cancer Chemotherapy and Biological Response Modifiers Annual 1998;18 (in press).
6. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer, Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45.
7. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesne in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-85.
8. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75.
9. Santoro A. Advanced soft tissue sarcoma: How many more trials with anthracyclines and ifosfamide? Ann Oncol 1999;10.
10. Blackledge G, van Oosterom AT, Mouridsen HT, et al. Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease. Eur J Cancer Clin Oncol 1990;26:134-41.
11. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Docetaxel (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53(5):1037-42.
12. Hortobagyi G. An expanding role for docetaxel. Semin Oncol 1998;25:(6 Suppl 13):1-3.
13. Van Hoesel QGCM, Verweij J, Catimel G, et al. Phase II study with Docetaxel (Taxotere ®) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994;5:539-42.
14. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trial, 1989;10:1-10.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
17. Edmonson JH, Ebbert LP, Nascimento AG, et al. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol (CCT) 1996;19:574-6
18. Verweij J, Judson I, Crowther D, et al. Randomized study comparing docetaxel (Taxotere® (T) to doxorubicin (D) in previously untreated soft tissue sarcomas (STS). Proc. Am Soc Clin Oncol 1997;16:496a.
19. Bramwell V, Blackstein M, Belanger K, et al. A phase II study of docetaxel in chemotherapy-naive patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma 1998;2:29-33.